Compare Summit Therapeutics Inc (SMMT) vs iShares Broad USD Investment Grade Corporate Bond (USIG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Summit Therapeutics Inc vs iShares Broad USD Investment Grade Corporate Bond — how do they compare? Summit Therapeutics Inc trades at $15.19 (market cap $12.06B), while iShares Broad USD Investment Grade Corporate Bond trades at $50.26. The key difference: Summit Therapeutics Inc is trading nearer its 52-week high, iShares Broad USD Investment Grade Corporate Bond nearer its low. Which is the better fit depends on your goals.
| SMMT | USIG | |
|---|---|---|
Market Cap | $12.06B | — |
Sector | Health | Fixed Income |
52-Week High | $26.98 | $52.69 |
52-Week Low | $12.55 | $50.18 |
Enterprise Value | $11.39B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Summit Therapeutics (SMMT) trades at $15.23, up 2.42% today, with a bullish technical signal and strong analyst consensus. The stock shows mixed earnings performance but benefits from positive news on ivonescimab's regulatory progress and clinical expansions. Despite negative profitability metrics, investor sentiment is buoyed by a high price target of $38.00 and recent partnership announcements in cancer drug development.
Outlook hinges on FDA approval for ivonescimab by November 2026, offering significant upside if successful. Risks include cash burn, ongoing losses, and fiduciary investigations. The stock presents a high-risk, high-reward opportunity for speculative investors betting on clinical successes.
USIG trades at $50.26, up 0.16% on the day, with a bearish technical signal from moving averages. Recent corporate actions include dividend payments, with the latest being $0.21 per share. The company's subsidiaries maintained credit ratings following a transaction with Tiptree Inc., as noted by AM Best on July 30, 2026.
The outlook is mixed, with technical indicators signaling caution, but institutional interest is present, as Bank of New York Mellon Corp increased its stake. Key risks include market volatility and execution of corporate strategies. The stock presents opportunities for income-focused investors due to dividends, but requires monitoring of fundamental developments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →About iShares Broad USD Investment Grade Corporate Bond
USIG is a low-cost ETF providing broad exposure to over 11,000 U.S. investment-grade corporate bonds. It tracks the ICE BofA US Corporate Index, featuring high-quality debt from 2026 leaders like Citigroup, Bank of America, and Oracle.
Read more on USIG →
